Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose M012 study in healthy adult male volunteers
ACTRN12616000093482Phase 3Recruiting
- Sponsor
- Merganser Biotech Australia
- Start
- Feb 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of M012 in beta thalassemia (2 arms), sponsored by Merganser Biotech Australia. Primary endpoint: Safety and tolerability of a single subcutaneous dose of M012. Started Feb 2016; status: recruiting.
02
Drugs
M012
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on ACTRN12616000093482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000093482.